Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.75 |
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29796237 | 0.94 | BCL2 (0.68) | BCL2BCL2L1 | |
| SCHEMBL29796421 | 0.93 | BCL2 (0.67) | BCL2BCL2L1 | |
| SCHEMBL29796430 | 0.92 | BCL2 (0.66) | BCL2BCL2L1 | |
| SCHEMBL30313840 | 0.92 | BCL2 (0.64) | BCL2BCL2L1CYP2C9 | |
| SCHEMBL1870326 | 0.92 | BCL2 (0.66) | BCL2BCL2L1 | |
| SCHEMBL29796456 | 0.92 | BCL2 (0.66) | BCL2BCL2L1 | |
| SCHEMBL1871052 | 0.91 | BCL2 (0.74) | BCL2BCL2L1 | |
| SCHEMBL29403314 | 0.91 | BCL2 (0.74) | BCL2BCL2L1 | |
| SCHEMBL29796424 | 0.90 | BCL2 (0.68) | BCL2BCL2L1 | |
| SCHEMBL2724283 | 0.90 | BCL2 (0.66) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-115210259-A | Use of anti-CCR 7 antibodies in combination therapy with BTK inhibitors and/or BCL2 inhibitors for the treatment of hematologic malignancies | 弹射器治疗有限公司 | 2022-10-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885CYP2C9 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.